Viridian Therapeutics Inc (NAS:VRDN)
$ 12.34 0.74 (6.38%) Market Cap: 787.57 Mil Enterprise Value: 347.92 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 46/100

Q2 2022 Viridian Therapeutics Inc Earnings Call Transcript

Aug 15, 2022 / 12:00PM GMT
Release Date Price: $22 (+49.36%)
Operator

Greetings, and welcome to the Viridian Therapeutics conference call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the call over to John Jordan, Vice President of Investor Relations. Thank you. You may begin.

John A. Jordan
Viridian Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, Darryl. Good morning, everyone, and welcome to the Viridian conference call to discuss the initial clinical data for VRDN-001 in patients with thyroid eye disease.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these statements in light of new information or future events. Factors that could cause actual results or outcomes to differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot